European journal of hospital pharmacy : science and practice最新文献

{"title":"Environmentally responsible use of hospital infusion systems: a systematic review of the literature.","authors":"Eleonore Martin, Laura Négrier, Florence Lallemant, Pascal Odou, Morgane Masse, Bertrand Décaudin","doi":"10.1136/ejhpharm-2025-004536","DOIUrl":"10.1136/ejhpharm-2025-004536","url":null,"abstract":"<p><strong>Background: </strong>The healthcare sector produces significant amounts of waste and harmful substances and consumes large amounts of energy; hence, it is also involved in the move towards sustainability. Plastics are everywhere in hospitals (especially in medical devices used for infusion) and contribute significantly to greenhouse gas emissions. The objective was to review the scientific literature on ways of making in-hospital infusion practices more environmentally friendly.</p><p><strong>Methods: </strong>The literature data were reviewed systematically and independently by two investigators and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Any differences of opinion were resolved by a third investigator. Four online databases (PubMed, Embase, ScienceDirect and Web of Science) were searched for articles published in English or French between 1 January 2004 and 31 December 2024. Only publications that address sustainable development and infusion medical devices were included. The following data were extracted: country, hospital department(s), and the study's objectives, methods, main results and conclusions. The robustness of the selected studies was assessed using the Mixed Methods Appraisal Tool.</p><p><strong>Results: </strong>In all, 1938 publications were screened, and eight were included. Four publications concerned overconsumption and/or waste analysis, one compared single-use devices with reusable devices, and three were concerned with intravenous drug administration and wastage. The topics addressed in life cycle assessments were procurement, supply, storage, overconsumption of medical devices, the wastage of intravenous drugs and waste management.</p><p><strong>Conclusion: </strong>The results highlighted some areas for improvement at various points in the medical device life cycle-from manufacturing to recycling. Collaboration between hospital stakeholders is essential for the promotion of environmentally friendly infusion practices.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"414-422"},"PeriodicalIF":1.5,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145653992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmaceutical consultation on patients receiving oral antineoplastic agents: a systematic review.","authors":"João Pedro Fernandes, Ana Margarida Advinha, Sofia Oliveira-Martins","doi":"10.1136/ejhpharm-2025-004586","DOIUrl":"10.1136/ejhpharm-2025-004586","url":null,"abstract":"<p><p>The management of oncological treatment has evolved substantially with the increasing use of oral antineoplastic agents, which are self-administered by patients or caregivers at home, and require careful monitoring and support. The aim of this study was to evaluate the impact of pharmaceutical consultations on oncology patients undergoing therapy with oral antineoplastic agents. A systematic literature review was conducted using the PubMed, Scopus and Web of Science databases with the last search on 5 June 2025. Primary observational or experimental studies were sought for inclusion. Eligible studies assessed the outcomes of pharmaceutical consultations for oncology patients receiving oral antineoplastic therapy in a hospital setting, compared with a conventional medication dispensing model. The risk of bias in the included studies was evaluated using the Cochrane risk-of-bias tools, RoB-2 and ROBINS-I. The review was developed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 Statement, and the protocol for the systematic literature review was registered with PROSPERO under the reference CRD42024533367. From the 881 records initially identified, 16 studies were included. A backward reference search led to the inclusion of two additional publications, bringing the total to 18 studies in this systematic review. The main interventions performed by pharmacists during pharmaceutical consultations included patient education on their treatment, management of adverse reactions and drug interactions, and monitoring of adherence to therapy. The studies evaluated a total of 10 variables, demonstrating the benefits of pharmaceutical consultation in all of them. Significant benefits were observed in terms of progression-free survival and quality of life, both of which are crucial in cancer treatment. However, further research is required, particularly involving larger patient samples and studies spanning multiple institutions and countries. To facilitate a comprehensive and comparative evaluation of different pharmaceutical consultation models in oncology, it would be advantageous to standardise methods for assessing their impact.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"401-413"},"PeriodicalIF":1.5,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145713888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Women and adverse drug reactions: 56 years of analysis of real-world data collected in the FDA adverse event reporting system (FAERS) database.","authors":"Eleonora Castellana, M A Chiappetta","doi":"10.1136/ejhpharm-2025-004597","DOIUrl":"10.1136/ejhpharm-2025-004597","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"491-492"},"PeriodicalIF":1.5,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stability of alglucosidase alfa in 0.9% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements.","authors":"Ina Barzel, Jan-Dietert C Brugma, Edwin H Jacobs, Marianne Hoogeveen-Westerveld, P Hugo M van der Kuy, Tim Preijers","doi":"10.1136/ejhpharm-2025-004516","DOIUrl":"10.1136/ejhpharm-2025-004516","url":null,"abstract":"<p><strong>Objectives: </strong>Enzyme replacement therapy (ERT) with alglucosidase alfa is the cornerstone of treatment for Pompe disease, a rare disorder caused by acid α-glucosidase (GAA) deficiency. Since 2008, home infusions have been provided in the Netherlands. However, the short shelf-life of the ready-to-administer infusions poses challenges for manufacturing and dispensing pharmacies. This study assessed the stability of ready-to-administer alglucosidase alfa infusions by determining enzyme activity and cellular uptake of two concentrations during 11 days of storage.</p><p><strong>Methods: </strong>Alglucosidase alfa infusions (2 and 4 mg/mL in 0.9% sodium chloride) were prepared and samples were drawn on days 1 to 7 and 11. Enzyme activity was determined using 4-methylumbelliferyl-α-D-glucoside (4MU-αGlc) and glycogen as substrates. Additionally, enzyme uptake in cultured fibroblasts was investigated.</p><p><strong>Results: </strong>There was no difference in enzyme activity after 11 days as compared with day 1 using 4MU-αGlc (2 mg/mL: 352 vs 331 nmol/h/mL; 4 mg/mL: 657 vs 662 nmol/h/mL) or glycogen (2 mg/mL: 183 vs 176 nmol/h/mL; 4 mg/mL: 352 vs 357 nmol/h/mL). Uptake of alglucosidase alfa in fibroblasts remained stable over 11 days, with activity ranging from 90 to 104 nmol/h/mL at 2 mg/mL and from 233 to 238 nmol/h/mL at 4 mg/mL. Linear regression analysis confirmed no statistically significant association between time and enzyme activity or uptake.</p><p><strong>Conclusions: </strong>Ready-to-administer alglucosidase alfa infusion in 0.9% sodium chloride at 2-4 mg/mL is stable for 11 days when stored at 2-8°C or -20°C and protected from light. Extending the stability could enhance efficiency and flexibility for infusion preparation and home delivery, while minimising pharmaceutical waste.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"450-454"},"PeriodicalIF":1.5,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13539857/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144872145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacological resilience in the context of geopolitical tensions: a European perspective.","authors":"Eduardo Tejedor-Tejada, Iván Cores-Rodríguez, Carlos José Cortes Sánchez","doi":"10.1136/ejhpharm-2025-004587","DOIUrl":"10.1136/ejhpharm-2025-004587","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"490-491"},"PeriodicalIF":1.5,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for unintentional medication discrepancies identified through pharmacy staff-led medication reconciliation to prioritise patients in the emergency department: a rapid review.","authors":"Busra Dinc, Charlotte Olesen, Faruk Coric, Helle Houlbjerg Carlsen","doi":"10.1136/ejhpharm-2025-004526","DOIUrl":"10.1136/ejhpharm-2025-004526","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to identify the risk factors associated with unintentional medication discrepancies identified through pharmacy staff-led medication reconciliation in emergency departments across multiple countries. The long-term goal is to support the development of a model to systematically prioritise patients at high risk in these settings.</p><p><strong>Methods: </strong>This rapid review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. A literature search of the PubMed database was performed on 8 October 2024. Studies were selected based on predefined eligibility criteria defined by the PICO framework- Population: adult emergency patients (aged ≥18 years) admitted to the emergency department; Intervention: medication reconciliation conducted by pharmacy staff; Comparator: standard medication reconciliation or standard care; Outcome: risk factors for unintentional medication discrepancies identified through pharmacy staff-led medication reconciliation in the emergency department. All included studies were qualitatively assessed.</p><p><strong>Results: </strong>The literature search yielded 433 citations, of which 15 studies met the eligibility criteria. The included studies primarily investigated patient, medication and setting-related risk factors, encompassing a total of 15 264 patients who received pharmacy staff-led medication reconciliation in emergency departments across seven countries. A consistent pattern of risk factors emerged, including advanced age and polypharmacy. Only one study found that admissions during night-time or weekend hours were significantly associated with medication discrepancies. Differences in health IT systems and reconciliation practices were also noted across countries.</p><p><strong>Conclusions: </strong>Advanced age and polypharmacy were consistently associated with unintentional medication discrepancies. Future research should address variations in health IT systems and focus on developing robust prioritisation models to optimise medication reconciliation processes and improve patient safety. Increasing pharmacy staff capacity may further support this goal.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"395-400"},"PeriodicalIF":1.5,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moxifloxacin-induced insomnia with psychotic episodes in a toddler: a case report.","authors":"Violeta Getova-Kolarova, Ines Hababa-Ivanova, Nicoleta Georgieva","doi":"10.1136/ejhpharm-2025-004600","DOIUrl":"10.1136/ejhpharm-2025-004600","url":null,"abstract":"<p><p>Moxifloxacin is a fourth-generation fluoroquinolone with a broad spectrum of antibacterial activity. It is commonly used for both local and systemic applications. Data on the safety profile of fluoroquinolones indicate the potential for serious adverse reactions including neurological and psychiatric disturbances. The current case describes the off-label use of moxifloxacin eye drops for nasal administration in a toddler which led to insomnia and symptoms of severe psychosis. Notably, these adverse events resolved completely shortly after discontinuation of treatment. This case highlights a rare and potentially debilitating adverse reaction and underscores the critical importance of clinical judgement when prescribing off-label medicines in the paediatric population.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"483-485"},"PeriodicalIF":1.5,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145079974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stability of caffeine citrate intravenous dilutions in sodium chloride and glucose solutions.","authors":"Grzegorz Szynkaruk, Marta Puchalska, Julia Kerner, Marta Karaźniewicz-Łada, Joanna Sobiak","doi":"10.1136/ejhpharm-2025-004706","DOIUrl":"10.1136/ejhpharm-2025-004706","url":null,"abstract":"<p><strong>Objectives: </strong>Caffeine citrate, a methylxanthine derivative, is commonly used in the management of apnoea of prematurity. In clinical settings, particularly in neonatal intensive care units, various dilutions of caffeine citrate in intravenous fluids are required to ensure precise and individualised dosing for extremely low birth weight infants. This study aimed to assess the stability of caffeine citrate solutions at concentrations of 1 mg/mL and 12.5 mg/mL in 0.9% w/v sodium chloride and 5% w/v glucose, stored at room temperature and under refrigeration up to 48 hours.</p><p><strong>Methods: </strong>Caffeine citrate concentrations were measured using a high-performance liquid chromatography method with ultraviolet detection (HPLC-UV). Solutions were stored at room temperature (22°C) and at 8°C for up to 48 hours. Two solvents for caffeine citrate were studied: normal saline (0.9% w/v sodium chloride), and 5% w/v glucose. The calibration curves of the HPLC-UV method were linear over the range of 0.1-12.5 mg/mL for both types of intravenous fluid. The stability criterion was defined according to International Council for Harmonisation (ICH) M10 (±15% of nominal concentration), and compliance with the stricter United States Pharmacopeia (USP) criterion (±10%) was also assessed.</p><p><strong>Results: </strong>All samples remained within the ICH M10 acceptance limits. Most results also complied with the USP±10% threshold; however, three values (12.5 mg/mL in 0.9% w/v sodium chloride at 24 hours refrigerated, and 1 mg/mL in 5% w/v glucose at 24 hours and 48 hours refrigerated) exceeded 110% (112.9%, 111.3%, and 111.4%, respectively).</p><p><strong>Conclusions: </strong>Caffeine citrate diluted in 0.9% w/v sodium chloride or 5% w/v glucose is chemically stable at concentrations of 1 mg/mL and 12.5 mg/mL for up to 48 hours when stored at room temperature, meeting ICH and USP acceptance criteria in all cases. Caffeine citrate solutions did not meet the USP±10% criterion if stored at 8°C for 24 hours.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"474-478"},"PeriodicalIF":1.5,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145713898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update on the hospital pharmacist profile: from clinical practice to management.","authors":"Eduardo Tejedor-Tejada, Daniel Ortiz Del Olmo, Ivan Cores-Rodríguez","doi":"10.1136/ejhpharm-2025-004564","DOIUrl":"10.1136/ejhpharm-2025-004564","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"490"},"PeriodicalIF":1.5,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypoglycaemic coma induced by a falsified semaglutide product: a case report.","authors":"Giulia Antonacci, Erika Bortignon, Massimo Bolognesi, Salvatore Silvio Piano, Alessandro Cadore, Laura Camuffo, Francesca Venturini, Sonia Faoro, Donata Favretto, Antonietta Romano, Daniele Mengato","doi":"10.1136/ejhpharm-2025-004656","DOIUrl":"10.1136/ejhpharm-2025-004656","url":null,"abstract":"<p><p>Semaglutide (Ozempic, Rybelsus, Wegovy) is a GLP-1 receptor agonist used for the treatment of type 2 diabetes and, more recently, weight management. Due to its efficacy in weight loss, semaglutide has gained worldwide popularity, particularly the branded version Ozempic, resulting in off-label use by people seeking rapid weight loss. The resulting high demand has led to an increase in falsified products sold by unregulated online marketplaces. We present a case of a 31-year-old woman who was admitted to the emergency room in a hypoglycaemic coma after self-administrating semaglutide (Ozempic) obtained from a website. Toxicological analysis showed that the vial contained insulin instead of semaglutide, therefore leading to severe hypoglycaemia. This case highlights the growing concern regarding falsified medicines sold in the online drug market and the associated risk of severe adverse events. We reported the case to the Italian Medicines Agency (AIFA) and local authorities. We propose regulatory measures to mitigate similar incidents in the future.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"486-489"},"PeriodicalIF":1.5,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145344438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}